Skip to ContentSkip to Navigation
Over onsFaculty of Science and EngineeringOnderzoekGRIPPharmacoTherapy, -Epidemiology & -Economics (PTEE)Publications

Publications 2006

Below our publications are listed using several headings. Scientific publications relate to original research, often published internationally, but also in the Dutch language. Professional publications are in Dutch and relate to reviews and expressions of opinions.

A few publications have no links. Reprints can be requested by our secretary

Scientific publications international
1. Atthobari J, Brantsma A, Gansevoort RT, Visser S, Asselbergs F, van Gilst W, de Jong PE, de Jong-van den Berg LTW. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both randomized clinical trial and an observational cohort study.
Nephrology Dialiysis Transplantation 2006;may 23:1-9.
2. Atthobari J, Asselbergs F, Boersma C, de Vries R, Hillege H, van Gilst W, Gansevoort RT, de Jong PE, de Jong-van den Berg LTW, Postma MJ. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmavoeconomic analysis linked to the Prevention of REnal and Vascular ENdstage Disease (PREVEND) study and the prevention of REnal and Vascular ENdstage Disease Intervention Trial (PREVEND IT). Clinical Therapeutics 2006;28(3):432-44.
3. Bakker M, Jentink J, Vroom F, van den Berg PB, de Walle HEK, de Jong-van den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG An International Journal of Obstetrics and Gynaecology 2006;113:559-68.
4. Boersma C, Atthobari J, Gansevoort RT, de Jong-van den Berg LTW, de Jong PE, de Zeeuw D, Annemans L, Postma MJ. Pharmacoeconomics of angiotensin II antagonists in Type 2 diabetic patients with Nephropathy. Pharmacoeconomics 2006;24(6):523-35.
5. Boersma C, Radeva J, Koopmanschap M, Voors A, Postma MJ. Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to the Netherlands. Journal of Medical Economics 2006;9:121-31.
6. Bos J, Rümke H, Welte R, Spanjaard L, van Alphen L, Postma MJ. Combination vaccine against invasive meningococcal B and pneumococcal infections. Pharmacoeconomics 2006;24(2):141-53.
7. Bos JM, Postma MJ. The authors' reply. (Discounting health effects in pharmacoeconomic evaluations: current controversies. Birks, S. Pharmacoeconomics 2006;24(12)1273-4 ). Pharmacoeconomics 2006;24(12):1275-6.
8. Faber A, Kalverdijk L, de Jong-van den Berg LTW, Hugtenburg J, Minderaa RB, Tobi H. Parents report on stimulant-treated children in the Netherlands: Initiation of treatment and follow-up care. Journal of Child and Adolescent Psychopharmacology 2006;16(4):432-40.
9. Jansman FGA, Postma MJ. Costs of chemotherapy in the treatment of colorectal cancer. European Journal of Health Economics 2006;2(7):145-6.
10. de Jong-van den Berg LTW, Faber A, van den Berg PB. HRT use in 2001 and 2004 in the Netherlands - A world of difference. Maturitas 2006;54:193-7.
11. de Jong-van den Berg LTW. Letter to the Editors. Reply: Trends and predictors of folic acid awareness Am J Obstet Gynecol 2005;192:121-8. American Journal of Obstetrics and Gynecology 2006;194(6):1741-(letter).
12. Kho Y, Jansman F, Prins N, Neef C, Brouwers JRBJ. Population pharmacokinetics of Oxaliplatin ( 85 mg/m2 ) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Therapeutic Drug Monitoring 2006;28:206-11.
13. Klok RM, Boersma C, Oosterhuis I, Visser S, de Jong-van den Berg LTW. Switch patterns before and after patent expiry of omeprazole: a case study in the Netherlands. Alimentary Pharmacology & Therapeutics 2006;23:1595-600.
14. Krapels I, Zielhuis G, Vroom F, de Jong-van den Berg LTW, Kuijpers-Jagtman A-M, Mink van der Molen A, Steegers-Theunissen R.
Periconceptional health and lifestyle factors of both affect the risk of live-born children with orofacial clefts. Birth Defects Research 2006;76(part A):613-20.
15. Lub R, Denig P, van den Berg PB, Hoogenberg K, de Jong-van den Berg LTW. The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of type 2 diabetes mellitus. British Journal of Clinical Pharmacology 2006;62(6):660-5.
16. Meijer WM, de Jong-van den Berg LTW, van den Berg M, Verheij J, de Walle HEK. Clomiphene and Hypospadias on a detailed level: signal or change? Birth Defects Research 2006;76(a):249-52.
17. Meijer WM, Cornel MC, Dolk H, de Walle HEK, Armstrong N, de Jong-van den Berg LTW. The potential of the European network of congenital anomaly registers (EUROCAT) for drug safety surveillance: a descroptive study. Pharmacoepidemiology and Drug Safety 2006;15:675-82.
18. Meijer WM, Werler MM, Louik C, Hernandez-Diaz S, de Jong-van den Berg LTW, Mitchell AA. Can folic acid protect against congenital heart defects in Down Syndrome? Birth Defects Research (part A) 2006;Clinical and molecular Teratology 76:714-7.
19. Morré SA, Spaargaren J, Veldhuijzen I, Postma MJ, van Bergen JEAM. Evaluation of the leukocyte esterase test (LET) as pre-sreening test to reduce costs for national population-based Chlamydia trachomatis screening programs. Journal of Adolescent Health 2006;38(letter):332-5.
20. Naunton M, Duyvendak M, Peterson GM, Brouwers JRBJ. Practice patterns in osteoporosis prevention in patients on glucocorticoids.
Osteoporos Int 2006;17(letter):634-5.
21. Naunton M, al Hadithy AFY, Brouwers JRBJ, Archer D. Estradiol gel: review of the pharmaogology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause 2006;13(3):517-27.
22. Postma MJ, Baltussen RMPM, Palache MA, Wilschut J. Further evidence for favorable cost-effectiveness of elderly influenza vaccination.
Expert Rev Pharmacoeconomics Outcomes Res 2006;6(2):215-27.
23. Schirm E, de Vries T, Tobi H, van den Berg PB, de Jong-van den Berg LTW. Prescribed doses of inhaled steroids in Dutch children: too little or too much, for too short a time. British Journal of Clinical Pharmacology 2006;62(4):383-90.
24. Smink BE, Mathijssen MPM, Lusthof KJ, de Gier JJ, Egberts ACG, Uges DRA. Comparison of urine and oral fluid as matrices for screening of thirty-three benzodiazepines and benzodiazepine-like substances using immunoassay and LC-MS9-MS). Journal of Analytical Toxicology 2006;30:478-85.
25. Tolley K., Postma MJ. Pharmacoeconomics and market access in Europe: case studies in Scotland and the Netherlands.
ISPOR Connections 2006;12(5):3-6.
26. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg LTW, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006;62(10):863-70.
27. Vonkeman H, Brouwers JRBJ, van de Laar MAFJ. Understanding the NSAID related risk of vascular events. BMJ 2006;332:895-8.
28. de Vries R, van Bergen JEAM, de Jong-van den Berg LTW, Postma MJ. Systematic screening for chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data. Value in Health 2006;9(1):1-11.
29. de Vries T, Tobi H, Schirm E, van den Berg PB, Duiverman E, de Jong-van den Berg LTW.
The gap between evidence-based medicine and daily practice in the management of paediatric asthma. A pharmacy-based population study from the Netherlands. Eur J Clin Pharmacol 2006;62:51-5.
30. de Vries T, de Langen-Wouterse J, van Puijenbroek EP, Duiverman E, de Jong-van den Berg LTW. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol 2006;62:343-6.
31. Vroom F, de Walle HEK, van de Laar MAFJ, Brouwers JRBJ, de Jong-van den Berg LTW. Disease-modifying antirheumatic drugs in pregnancy. Drug Safety 2006;29(10):845-63.
32. Zito JM, Tobi H, de Jong-van den Berg LTW, Fegert JM, Safer DJ, Janhsen K, Hansen DG, Gardner JF, Glaeske G. Antidepressant prevalence for youths: a Multi-national comparison. Pharmacoepidemiology and Drug Safety 2006;15:793-8.
Scientific publications national
1. de Jong-van den Berg LTW. SSRI's en de kans op persisterende pulmonale hypertensie bij de pasgeborene. Geneesmiddelenbulletin 2006;40(5):55-6.
2. de Jong-van den Berg LTW, Bakker M, de Walle HEK, van den Berg PB. Duidelijk verhoogd risico op congentiale afwijkingen door het gebruik van angiotensineconverterend-enzym (ACE)-remmers in de zwangerschap.
Ned Tijdschr Geneesk 2006;150(40):2222-3.
Professional publications
1. Boersma C, Postma MJ. Valsartan reduceert ziekenhuiskosten. Pharmaceutisch Weekblad 2006;4:137-9.
2. Brouwers JRBJ, al Hadithy AFY. Geneesmiddel belicht: sarcosine. Foliolum 2006;XX(II):32.
3. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Massive venenreizungen durch periphere applikation einer hyperosmolaren lösung. Krankenhauspharmazie 2006;27(10):450.
4. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Asthmaspray zur milbenbekämfung.
Krankenhauspharmazie 2006;27(5):215.
5. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Expertenwissen als ultima ratio?
Krankenhauspharmazie 2006;27(9):405.
6. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Ineffektive therapieeinstellung durch nichtbeachtung von interaktionen. Krankenhauspharmazie 2006;27(7):312.
7. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Medikationsfehler können auch durch den patienten verursacht werden. Krankenhauspharmazie 2006;27(8):358.
8. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Fehler bei zytostatika-gabe trots (oder wegen) computerunterstütztem ärtzlichem bestellsystem. Krankenhauspharmazie 2006;27(2):70.
9. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Fehler im dosisintervall: die woche wird zum tag ...
Krankenhauspharmazie 2006;27(3):113.
10. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Ähnlich klingende Namen von wirkstoffen und fertigarzneimitteln als risiko bei der verordnung. Krankenhauspharmazie 2006;27(4):162.
11. Erdmann H, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Kritische überprüfung einer sonderanforderung verhindert blutungen. Krankenhauspharmazie 2006;27(1):35.
12. Faber A, de Jong-van den Berg LTW. Boven 50 jaar niet doorgaan met orale anticonceptiva. Interventie per brief sorteert effect.
Pharmaceutisch Weekblad 2006;41:1295.
13. de Gier JJ. Innovatieve farmaceutische zorgconcepten. Tijdschrift voor Toekomstverkenning, strategieontwikkeling en Innovatie 2006;1:33-4.
14. Mang B, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Mission impossible. Krankenhauspharmazie2006;27(11):510.
15. Mang B, Heinemann D, Hoppe-Tichy T, Reissner P, Schnurrer JU, Taxis K. Zum ersten, zum zweiten und zum dritten .... Krankenhauspharmazie 2006;27(12):541.
16. de Vries R, Boersma C, Postma MJ. Scheve verdeling ziekenhuisopnames compliceert kostenanalyse. Valkuilen bij beoordeling kostenreductie. Pharmaceutisch Weekblad 2006;15:522-3.
Chapter in Book
1. Brouwers JRBJ. Maag en darm ziekten. In: van Everdingen, ed. Het Medisch Handboek. Orde van Medisch specialisten ed. Utrecht/Antwerpen: Kosmos Uitgevers, 2006.
2. Brouwers JRBJ. Gastroenterologie. In: van Everdingen & Glerum, ed. Diagnose en therapie Jaarboek.Houten: Bohn Satfleu van Loghum, 2006.
3. de Gier J. Farmaceutische Patiëntenzorg: zorgpraktijk in perspectief. In: Hof H, van Wijck F, van der Wijst G, eds. Farma Merk Waardig.Amsterdam/Tereringen: Farma Innovatie Discussie Platform FIDP, 2006:115-20.
Laatst gewijzigd:19 april 2016 09:34